There was no influence on the CD45 + CD11b macrophage population in the brain from the different treatments, indicating that neither FUS exposure, IL-12 administration, nor combined did not triggered macrophage-enhanced differentiation and invasion in the tumor region (Figure 4(D)). The gene discussed is ITGAM; the disease is neoplasm.